Loading...
XSWX
MED
Market cap1.41bUSD
Dec 05, Last price  
91.10CHF
1D
2.94%
1Q
-0.65%
IPO
45.76%
Name

Medartis Holding AG

Chart & Performance

D1W1MN
XSWX:MED chart
P/E
320.67
P/S
5.03
EPS
0.28
Div Yield, %
Shrs. gr., 5y
1.11%
Rev. gr., 5y
11.55%
Revenues
225m
+6.05%
82,302,85092,502,392105,040,292121,324,702130,143,937127,645,985159,880,236182,824,418212,006,000224,831,000
Net income
4m
+469.95%
7,270,9493,314,395866,5214,201,9072,146,521-943,5656,837,867-5,782,888619,0003,528,000
CFO
28m
+41.13%
11,877,11711,908,64011,012,9946,449,4648,114,01712,610,80620,952,678-3,927,46019,962,00028,173,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide. Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. The company offers osteosynthesis instruments for the areas of the hand, wrist, elbow, shoulder, and foot and ankle, as well as for the areas of the mandible, midface, orthognathic, and cranium under the APTUS and MODUS names. The company serves the surgeons, hospitals, and medical centers, as well as group purchasing organizations. Medartis Holding AG was founded in 1997 and is headquartered in Basel, Switzerland.
IPO date
Mar 23, 2018
Employees
858
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT